KSE
Search
- Page Path
- HOME > Search
Systematic Review
- The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies
- Mozhgan Ahmadinezhad, Maedeh Arshadi, Elahe Hesari, Maedeh Sharafoddin, Hosein Azizi, Farzad Khodamoradi
- Epidemiol Health. 2022;44:e2022050. Published online May 30, 2022
- DOI: https://doi.org/10.4178/epih.e2022050
- 10,721 View
- 343 Download
- 8 Web of Science
- 6 Crossref
-
Abstract
Summary
PDF
Supplementary Material -
AbstractA previous meta-analysis, entitled “The association between metabolic syndrome and bladder cancer susceptibility and prognosis: an updated comprehensive evidence synthesis of 95 observational studies involving 97,795,299 subjects,” focused on all observational studies, whereas in the present meta-analysis, we focused on cohort studies to obtain more accurate and stronger evidence to evaluate the association between metabolic syndrome and its components with bladder cancer. PubMed, Embase, Scopus, and Web of Science were searched to identify studies on the association between metabolic syndrome and its components with bladder cancer from January 1, 2000 through May 23, 2021. The pooled relative risk (RR) and 95% confidence intervals (CI) were used to measure this relationship using a random-effects meta-analytic model. Quality appraisal was undertaken using the Newcastle-Ottawa Scale. In total, 56 studies were included. A statistically significant relationship was found between metabolic syndrome and bladder cancer 1.09 (95% CI, 1.02 to 1.17), and there was evidence of moderate heterogeneity among these studies. Our findings also indicated statistically significant relationships between diabetes (RR, 1.23; 95% CI, 1.16 to 1.31) and hypertension (RR, 1.07; 95% CI, 1.01 to 1.13) with bladder cancer, but obesity and overweight did not present a statistically significant relationship with bladder cancer. We found no evidence of publication bias. Our analysis demonstrated statistically significant relationships between metabolic syndrome and the risk of bladder cancer. Furthermore, diabetes and hypertension were associated with the risk of bladder cancer.
-
SummaryKey Message
In this meta-analysis study, an attempt was made to investigate the relationship between metabolic syndrome and its components with bladder cancer, and as a result of this study, the relationship between metabolic syndrome and its components such as diabetes, high blood pressure, and bladder cancer was observed. Metabolic syndrome is more common among middle-aged and elderly people, and the elderly population is increasing worldwide, so the prevalence of this disease shortly may affect the healthcare system. Therefore, with correct health policies in all societies, the exorbitant costs that this disease brings can be avoided.Citations
Citations to this article as recorded by
- The causal relationship between osteoarthritis and bladder cancer: A Mendelian randomization study
Xi Zhang, Zengjin Wen, Zixuan Xing, Xiaoyu Zhou, Zhiluo Yang, Ruijun Dong, Jiao Yang
Cancer Medicine.2024;[Epub] CrossRef - Machine learning algorithms predicting bladder cancer associated with diabetes and hypertension: NHANES 2009 to 2018
Siying Xu, Jing Huang
Medicine.2024; 103(4): e36587. CrossRef - Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania
Adomas Ladukas, Ausvydas Patasius, Marius Kincius, Mingaile Drevinskaite, Justinas Jonusas, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte
Cancer Causes & Control.2024;[Epub] CrossRef - Observational study of in-hospital mortality risk from bladder cancer: Five years of experience at a tertiary referral hospital in Indonesia
Wahjoe Djatisoesanto, Yufi Aulia Azmi, Ida Bagus Gde Tirta Yoga Yatindra, Sony Wibisono Mudjanarko, Sri Umijati
Medicine.2024; 103(34): e39412. CrossRef - Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors
Ibrahim Jubber, Sean Ong, Laura Bukavina, Peter C. Black, Eva Compérat, Ashish M. Kamat, Lambertus Kiemeney, Nathan Lawrentschuk, Seth P. Lerner, Joshua J. Meeks, Holger Moch, Andrea Necchi, Valeria Panebianco, Srikala S. Sridhar, Ariana Znaor, James W.F.
European Urology.2023; 84(2): 176. CrossRef - The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study
Dorothea Strobach, Lisa Haimerl, Hanna Mannell, Christian G. Stief, Alexander Karl, Tobias Grimm, Alexander Buchner
Journal of Clinical Medicine.2023; 12(21): 6749. CrossRef
First
Prev
